Kyoung Jin Kim
Primary Care · Gardena, CANPI 1609392919
Payments from drug & device makers
Across 133 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$919
- Amgen$403
- Bayer$397
- Lilly USA, LLC$260
- Exact Sciences$152
- Boehringer Ingelheim$103
- plus $564 from 11 others
What the payments were for
- Food & beverage$2,798100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $919 |
| Amgen | 20 | $403 |
| Bayer | 19 | $397 |
| Lilly USA, LLC | 10 | $260 |
| Exact Sciences | 6 | $152 |
| Boehringer Ingelheim | 4 | $103 |
| Sumitomo Pharma America, Inc. | 4 | $93 |
| Ironwood Pharmaceuticals, Inc | 4 | $84 |
| Radius Health, Inc. | 3 | $72 |
| Amarin Pharma, Inc. | 3 | $71 |
| Novartis | 3 | $55 |
| Shield Therapeutics Inc | 2 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Novo Nordisk | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| Gilead | 1 | $27 |
| AstraZeneca | 1 | $22 |
How this compares
$2,798 in reported general payments places this provider in the 90th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 140 | $131,554 |
| JardianceEmpagliflozin | 140 | $115,470 |
| VascepaIcosapent Ethyl | 254 | $101,500 |
| TrulicityDulaglutide | 56 | $56,276 |
| JanuviaSitagliptin Phosphate | 44 | $38,837 |
| ZenpepLipase/Protease/Amylase | 23 | $29,954 |
| FarxigaDapagliflozin Propanediol | 46 | $29,631 |
| EliquisApixaban | 17 | $23,745 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 69 | $20,959 |
| Lidocaine | 88 | $19,493 |
| LinzessLinaclotide | 29 | $19,438 |
| Icosapent Ethyl | 83 | $16,793 |
| ZtlidoLidocaine | 21 | $14,737 |
| KerendiaFinerenone | 17 | $13,586 |
| NamzaricMemantine Hcl/Donepezil Hcl | 19 | $12,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Namzaric | $919 | $163,245188 claims |
| Boehringer IngelheimJardiance, Tradjenta | $103 | $121,661152 claims |
| Lilly USA, LLCTrulicity | $260 | $56,27656 claims |
| AstraZenecaFarxiga, Symbicort | $22 | $32,05757 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $35 | $14,73721 claims |
| BayerKerendia | $397 | $13,58617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 706 primary care providers in California.
Other primary care in Gardena
- Flora LimGardena$3K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Joann BallPalm Desert$56K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.